ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,91%
DAX
19 848,77
-0,34%
Brent Oil
73,285
0,00%
Bitcoin
98 250,01
-0,44%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allarity Therapeutics Inc (ALLR)

  7. Allarity Therapeutics Inc (ALLR) Actualités

ALLR

Allarity Therapeutics (ALLR)

Allarity Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALLR
DateHeureSourceTitreSymboleSociété
19/11/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLRAllarity Therapeutics Inc
18/11/202414h00GlobeNewswire Inc.Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate AdvancementsNASDAQ:ALLRAllarity Therapeutics Inc
14/11/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLRAllarity Therapeutics Inc
14/11/202414h00GlobeNewswire Inc.Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational HighlightsNASDAQ:ALLRAllarity Therapeutics Inc
22/10/202414h00GlobeNewswire Inc.Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for StenoparibNASDAQ:ALLRAllarity Therapeutics Inc
10/10/202414h00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:ALLRAllarity Therapeutics Inc
03/10/202414h00GlobeNewswire Inc.Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor ProgramNASDAQ:ALLRAllarity Therapeutics Inc
01/10/202423h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
01/10/202423h32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLRAllarity Therapeutics Inc
16/09/202414h00GlobeNewswire Inc.Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer TrialNASDAQ:ALLRAllarity Therapeutics Inc
13/09/202414h45GlobeNewswire Inc.Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALLRAllarity Therapeutics Inc
11/09/202414h00GlobeNewswire Inc.Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)NASDAQ:ALLRAllarity Therapeutics Inc
10/09/202415h15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLRAllarity Therapeutics Inc
09/09/202422h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLRAllarity Therapeutics Inc
30/08/202422h05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALLRAllarity Therapeutics Inc
29/08/202423h57Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ALLRAllarity Therapeutics Inc
26/07/202415h00GlobeNewswire Inc.Allarity Therapeutics Announces Postponement of Annual Stockholders MeetingNASDAQ:ALLRAllarity Therapeutics Inc
26/07/202412h04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALLRAllarity Therapeutics Inc
24/07/202412h00GlobeNewswire Inc.Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized SharesNASDAQ:ALLRAllarity Therapeutics Inc
22/07/202412h30GlobeNewswire Inc.Allarity Therapeutics Outlines Company’s 2024 Progress and ObjectivesNASDAQ:ALLRAllarity Therapeutics Inc
27/06/202414h00GlobeNewswire Inc.Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining ComplianceNASDAQ:ALLRAllarity Therapeutics Inc
25/06/202414h00GlobeNewswire Inc.Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
20/05/202414h00GlobeNewswire Inc.Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementNASDAQ:ALLRAllarity Therapeutics Inc
14/05/202422h01GlobeNewswire Inc.Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity BalancesNASDAQ:ALLRAllarity Therapeutics Inc
08/05/202422h05Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:ALLRAllarity Therapeutics Inc
07/05/202415h30GlobeNewswire Inc.Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockNASDAQ:ALLRAllarity Therapeutics Inc
06/05/202414h00GlobeNewswire Inc.Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1NASDAQ:ALLRAllarity Therapeutics Inc
02/05/202414h00GlobeNewswire Inc.Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerNASDAQ:ALLRAllarity Therapeutics Inc
17/04/202415h10GlobeNewswire Inc.Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)NASDAQ:ALLRAllarity Therapeutics Inc
04/04/202415h15GlobeNewswire Inc.Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitNASDAQ:ALLRAllarity Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLR

Dernières Valeurs Consultées

EU
BNP
BNP Paribas
EU
ML
Michelin
EU
CAP
Capgemini
EU
VK
Vallourec
EU
PX4
SBF 120
EU
AF
Air FranceKLM
EU
BEL20
Bel 20
NYSE
JPM
JP Morgan Chase
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés